We investigated OS in patients following antiangiogenic treatments within AIMP1/2/3-high and -low expression sub-groups (Fig. 4) and the median survival in each group is reported for publicly available glioma datasets and the two clinical trial datasets in Supplementary Table S6. The gene discussed is AIMP1; the disease is central nervous system cancer.